Book description
Learn why some drug discovery and development efforts succeed . . .
and others fail
Written by international experts in drug discovery and development,
this book sets forth carefully researched and analyzed case studies of
both successful and failed drug discovery and development efforts,
enabling medicinal chemists and pharmaceutical scientists to learn
from actual examples. Each case study focuses on a particular drug and
therapeutic target, guiding readers through the drug discovery and
development process, including drug design rationale,
structure-activity relationships, pharmacology, drug metabolism,
biology, and clinical studies.
Case Studies in Modern Drug Discovery and Development begins
with an introductory chapter that puts into perspective the underlying
issues facing the pharmaceutical industry and provides insight into
future research opportunities. Next, there are fourteen detailed case
studies, examining:
-
All phases of drug discovery and development from initial idea to commercialization
-
Some of today's most important and life-saving medications
-
Drugs designed for different therapeutic areas such as
cardiovascular disease, infection, inflammation, cancer, metabolic
syndrome, and allergies
-
Examples of prodrugs and inhaled drugs
-
Reasons why certain drugs failed to advance to market despite
major research investments
Each chapter ends with a list of references leading to the primary
literature. There are also plenty of tables and illustrations to help
readers fully understand key concepts, processes, and technologies.
Improving the success rate of the drug discovery and development
process is paramount to the pharmaceutical industry. With this book as
their guide, readers can learn from both successful and unsuccessful
efforts in order to apply tested and proven science and technologies
that increase the probability of success for new drug discovery and
development projects.
Xianhai Huang, PhD, is a Principal Scientist at Merck Research
Laboratories. Dr. Huang is the inventor or co-inventor on more than
forty patents and patent applications. As a mentor in the
Schering-Plough chemistry postdoctoral program, Dr. Huang and his
group discovered novel synthetic applications of (diacetoxyiodo)
benzene and successfully applied the methodology to the total
synthesis of psymberin, an antitumor natural product.
Robert G. Aslanian, PhD, is an adjunct professor of chemistry
at William Paterson University and was formerly a Senior Director of
Medicinal Chemistry with the Schering-Plough Research Institute and
Merck Research Laboratories. Dr. Aslanian has over twenty-five years
of experience in the pharmaceutical industry. He is co-inventor on
thirty-eight U. S. patents and coauthor on sixty-seven scientific
articles and reviews.
